Business
Result of AGM
SkinBioTherapeutics plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the re-appointment of auditors and director remuneration. Key resolutions regarding the allotment of securities for cash, both generally and for acquisitions, also received significant backing, with votes for ranging from 80.84% to 81.34%, indicating shareholder confidence in the company's strategic financial flexibility. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Group") Result of Annual General Meeting 29 December 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed. Resolution Votes For Votes Against Votes Withheld 1. To receive the annual report and accounts 88,024,558 83.50% 17,391,981 16.50% 722,198 2. To re-appoint Gravita as auditor 96,998,314 92.15% 8,266,920 7.85% 873,503 3. To authorise Directors to determine Auditors renumeration 97,093,358 92.13% 8,296,876 7.87% 748,503 4. To authorise the Directors to allot relevant securities 85,828,638 80.90% 20,268,099 19.10% 42,000 5. To authorise the Directors to allot equity securities for cash without a pre-emptive offer to shareholders 85,771,888 80.84% 20,324,849 19.16% 42,000 6. To authorise the Directors to allot equity securities for cash in relation to an acquisition of other capital investment 85,782,499 81.34% 19,682,546 18.66% 673,692 An electronic copy of the Annual Report and Accounts is available and the results of the AGM will be available on the Company's website in due course at www.skinbiotherapeutics.com/investor-relations . -Ends- For more information please contact: SkinBioTherapeutics plc Stuart J. Ashman, CEO Emily Bertram, Group Finance Director +44 (0) 191 495 7325 Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Andrew Johnson James Todd +44 (0) 020 7496 3000 Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix ® , is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix ® ) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix ® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores . The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com .
View stock analysis, news, and events for Skinbiotherapeutics Plc